Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifinatamab deruxtecan - Daiichi Sankyo Company

Next Previous
Drug Profile

Ifinatamab deruxtecan - Daiichi Sankyo Company

Alternative Names: DS-7300; DS-7300a; I-DXd; MK-2400

Latest Information Update: 19 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Merck & Co
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer; Small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 12 Apr 2024 Daiichi Sankyo in collaboration with Merck Sharp & Dohme plans Ib/II IDeate-Lung03 trial in Small cell lung cancer (Combination therapy, First-line therapy) in June 2024 (IV) (NCT06362252)
  • 29 Mar 2024 Daiichi Sankyo plans a phase II trial for Solid tumors (Second-line therapy or greater, Metastatic disease) in March 2024 (NCT06330064)
  • 12 Jan 2024 Daiichi Sankyo in collaboration with Merck Sharp & Dohme plans a phase III IDeate-Lung02 (IDeate-2) trial for Small cell lung cancer (Second-line therapy or greater) (IV) in Japan, USA, Europe and Asia in March 2024 (NCT06203210)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top